Standard Chartered Expands Hedge Fund Access for Wealth Clients 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Add as a preferred source on Google
SAN DIEGO, May 08, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results on Monday, May 14, 2018 before the open of the U.S. financial markets. Company management will host a conference call and webcast on Monday, May 14, 2018 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss the results and provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 8255679.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 candidate is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
IMMEDIATE RELEASE
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
